Lipotecan | 1432468-79-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: Lipotecan
• 英文别名: [(19S)-8-[(dimethylamino)methyl]-19-ethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] 2-[(2,4,5,7-tetranitrofluoren-9-ylidene)amino]oxypropanoate
• CAS: 1432468-79-5
• 化学式: C39H30N8O15
• 分子量: 850.7
• InChiKey: JCCCLGDYMMTBPM-HXDHBHDHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  62
• 可旋转键数：
  8
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  314
• 氢给体数：
  1
• 氢受体数：
  18

文献信息

• NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF
  申请人：Kuo Min-Wen

  公开号：US20100227877A1

  公开（公告）日：2010-09-09

  The present invention provides two new camptothecin derivatives, which were identified as S,R- and S,S-topotecan lactates, respectively. Both compounds have anticancer activities. Pharmaceutical compositions of the new camptothecin derivatives, and cancer therapies with the new camptothecin derivatives or their pharmaceutical compositions were also provided.

  本发明提供了两种新的紫杉醇衍生物，分别被鉴定为S，R-和S，S-拓扑替康乳酸盐。这两种化合物均具有抗癌活性。同时还提供了这些新的紫杉醇衍生物的药物组合物，以及使用这些新的紫杉醇衍生物或其药物组合物进行癌症治疗的方法。
• DOSE REGIME FOR CAMPTOTHECIN DERIVATIVES
  申请人：Taiwan Liposome Company, Ltd.

  公开号：US20140135357A1

  公开（公告）日：2014-05-15

  The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.
• PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES
  申请人：Taiwan Liposome Company, Ltd.

  公开号：US20140294973A1

  公开（公告）日：2014-10-02

  The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention.
• US8168648B2
  申请人：——

  公开号：US8168648B2

  公开（公告）日：2012-05-01